Dupilumab in adolescents with moderate to severe atopic dermatitis: a 32‐week real‐world experience during the COVID‐19 pandemic. (1st January 2022) - Hansel, K.; Patruno, C.; Antonelli, E.; Dal Bello, G.; Napolitano, M.; Fabbrocini, G.; Grieco, T.; Pellacani, G.; Fargnoli, M. C.; Esposito, M.; Piras, V.; Zucca, M.; et al.